Subutex Sublingual 0.4 mg/2 mg/8 mg Tablet
PDF Leaflet Revision Date: 27 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Substitution treatment for opioid drug dependence.
Dosage (summary)
Initial dose: 0.8 mg to 4 mg daily; max: 16 mg.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Risk of neonatal withdrawal syndrome; contraindicated in breastfeeding.
Key Drug Interactions
- Benzodiazepines
- Alcohol
- CYP3A4 inhibitors
- Serotonergic drugs
Contraindications
- Hypersensitivity to buprenorphine
- Severe respiratory insufficiency
- Severe hepatic insufficiency
- Alcoholism
Common side effects
- Nausea
- Headache
- Insomnia
- Dizziness
Counselling Points
- Do not share medication.
- Monitor for signs of misuse.
- Avoid alcohol and CNS depressants.
Serious warnings
- Risk of respiratory depression
- Potential for misuse and addiction
- Seizure risk in predisposed patients
Important Disclaimer
The Subutex Sublingual 0.4 mg/2 mg/8 mg Tablet professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
